Clinical trial
Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic…
NCT00093808 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00093808 |
|---|---|
| Title | Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer |
| Official title | Phase II Study of Capecitabine in Combination With Vinorelbine and Trastuzumab for the First- or Second-LineTreatment of HER2+ Metastatic Breast Cancer |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, capecitabine, vinorelbine tartrate |
| Enrollment | 47 |
| Start date | Aug 1, 2004 |
| Primary completion | Dec 1, 2008 |
| Completion | May 1, 2013 |
| First posted | Oct 8, 2004 |
| Last update posted | Mar 6, 2017 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: